English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Feeble awake effects of plasminogen activator inhibitor type-1 in mice

MPS-Authors
/persons/resource/persons80499

Romanowski,  C. P. N.
AG Kimura, Mayumi, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80382

Jakubcakova,  V.
AG Kimura, Mayumi, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80324

Flachskamm,  C.
AG Kimura, Mayumi, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80397

Kimura,  M.
AG Kimura, Mayumi, Florian Holsboer (Direktor), Max Planck Institute of Psychiatry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Sakakibara, H., Romanowski, C. P. N., Jakubcakova, V., Flachskamm, C., Shimoi, K., & Kimura, M. (2011). Feeble awake effects of plasminogen activator inhibitor type-1 in mice. Behavioural Brain Research, 220(2), 354-357.


Cite as: https://hdl.handle.net/11858/00-001M-0000-000E-8E5C-6
Abstract
Plasminogen activator inhibitor-type 1 (PAI-1) is involved in the fibrinolytic system and shows its increased levels in diseases, e.g., obesity and sleep apnea syndrome. The aim of the study is to investigate whether PAI-1 affects sleep-wake patterns in mice. When recombinant mouse PAI-1 was administered intraperitoneally, only rapid but short increases in time spent awake were observed after 20 or 100 mu g/kg, although its plasma concentration was kept high for an hour. The results suggest that PAI-1 may serve its role rather as a marker than an initiator of disturbed sleep. (C) 2011 Elsevier B.V. All rights reserved.